News
Ambros' $125m for pain disorder drug, and other financings
Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
News
Lilly points to long-lasting weight loss with orforglipron
Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.
R&D
Europe has the tools to fight superbugs. Let’s use them.
Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help.
News
Takeda plans filings for Sotyktu rival on new psoriasis data
Takeda intends to file for approval of its oral psoriasis therapy zasocitinib next year, with Bristol Myers Squibb's Sotyktu in its sights.
R&D
FDA’s emerging framework to reduce animal testing: Implicati...
Exploring the strategic shift toward reducing reliance on non-human primates (NHPs) and other animal species in R&D.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
